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ABORTION POLITICS, SCIENCE, AND
RESEARCH ETHICS: TAKE DOWN THE
WALL OF SEPARATION*
John C. Fletcher, Ph.D. **
INTRODUCTION
Reflecting Bush Administration policy, in November 1989 Dr. Louis W.
Sullivan, Secretary of the United States Department of Health and Human
Services (HHS), rejected an expert panel's report to the Director of the Na-
tional Institutes of Health (NIH). By a vote of eighteen to three, the panel
advised that federal support of fetal tissue transplantation research (FTTR)
"was acceptable public policy" provided that twelve guidelines to prevent
abuses were adopted to regulate FTTR as part of the existing body of federal
regulations to protect human subjects.' The Advisory Committee to the Di-
rector of NIH had previously approved the panel's report by a unanimous
vote.2 Dr. Sullivan, however, "indefinitely" continued a moratorium on
FTTR that began in March 1988, reasoning primarily that the Administra-
tion and Congress opposed any funding of activities by HHS which "en-
courage or promote abortion." 3 Dr. Sullivan also stated: "I, however, note
* I thank the Editor for inviting me to contribute to this volume in honor of my
esteemed colleague, Walter J. Wadlington, and his contribution to the study and teaching of
health care law and public policy. Walter Wadlington continues to be a pioneer in
interdisciplinary work in law, medicine, and ethics. I am also grateful to Robert M. O'Neil and
John A. Robertson for their help and comments on First Amendment implications of this
subject. In addition, my thanks to Maureen A. Berkner who edited this Article with skill and
speed.
** Director, Center for Biomedical Ethics, Professor of Internal Medicine, Professor of
Religious Studies, University of Virginia; Chief, Bioethics Program, Warren G. Magnuson
Clinical Center, National Institutes of Health, Bethesda, Maryland (1977-87); B.A., 1953, Uni-
versity of the South; M. Div., 1956, Virginia Theological Seminary; Ph.D. (Christian Ethics),
1969, Union Theological Seminary, New York.
1. 1 CONSULTANTS TO THE ADVISORY COMM. TO THE DIRECTOR, NATIONAL INSTI-
TUTES OF HEALTH, REPORT OF THE HUMAN FETAL TISSUE TRANSPLANTATION PANEL 2
(1988) [hereinafter 1 CONSULTANTS TO THE ADVISORY COMM.].
2. ADVISORY COMM. TO THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH, REPORT
ON HUMAN FETAL TISSUE TRANSPLANTATION RESEARCH 7 (1988).
3. Letter from Louis B. Sullivan, M.D., Secretary, U.S. Department of Health and
Human Services, to William F. Raub, M.D., Acting Director, National Institutes of Health 1
(Nov. 2, 1989) (on file with author).
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that interest exists in the private sector in continuing such research. Thus,
whatever biomedical knowledge that may be obtained from such research
can be obtained without Federal subsidization."4 This action added one
more level to a growing "wall of separation"5 between federal and private
support for any clinical research associated with elective abortion or studies
that lead to the loss of human embryos in vitro. The Administration's policy
affects several types of clinical research associated with fetal diagnosis and
therapy, including the future of human gene therapy in either fetuses or in
live-born persons affected by genetic disorders.
6
This Article examines arguments for and against this policy. A wall of
separation between public and private support of religion is sound. A wall of
separation between public and private support of embryo and fetal research
is misplaced and destructive of clinical research, which ought to be guided
by scientific peer review and the ethical tenets that undergird research in-
volving human subjects.
This Article has four parts. The first part has three sections: 1) a descrip-
tion of the links among FTTR, fetal diagnosis, fetal therapy, and human
gene therapy; 2) an account of events leading up to and following the mora-
torium on FTTR; and 3) a description of the divergent ethical perspectives
on FTTR with a discussion of their strengths and weaknesses.
The second part places FTTR in the larger historical context of a transi-
tion in the federal sector of science from a policy of restriction to a policy of
separation of fetal and embryo research from federal support. The third part
challenges a position that would permanently separate public and private
support for these research activities. It sets out the reasons for a restoration
of research freedom to the federal sector of science. The final part enlarges
upon the Belmont Report7 for guidance in research ethics that apply to these
and other controversial activities.
4. Id. at 2.
5. The phrase "wall of separation" is attributed to Thomas Jefferson who used the term
to describe the intent and the effects of the First Amendment. For a reference to Jefferson's
statements about the clause against establishment of religion by law, see Everson v. Board of
Educ., 330 U.S. 1, 16 (1946); Reynolds v. United States, 98 U.S. 145, 164 (1878).
6. John C. Fletcher, Controversies in Research Ethics Affecting the Future of Human
Gene Therapy, 1 HUM. GENE THERAPY 307, 310 (1990).
7. NATIONAL COMM'N FOR THE PROTECTION OF HUM. SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES
FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH (1983) [hereinafter BELMONT
REPORT].
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I. USES OF FETAL TISSUE IN EXPERIMENTAL THERAPY
A. Links to Fetal Diagnosis, Therapy, and Human Gene Therapy
Investigators have used fetal tissue experimentally to treat some disorders
that are caused wholly or in part by genetic factors. For example:
1) The DiGeorge syndrome: A congenital anomaly in the development of
derivatives of the third and fourth pharyngeal pouches often involving defor-
mities of the ear, nose, mouth, and aortic arch. Human fetal thymus trans-
plants are known to be effective in the treatment of this syndrome.'
2) Diabetes mellitus-Type I: There is a clear genetic factor but an un-
known mode of inheritance.9 Islet cells from the fetal pancreas have been
the source for experimental therapy.' 0
3) Investigators have conducted studies on mice, sheep, and rhesus
monkeys and learned that fetal stem cells can be given to pre-immune fetuses
without use of immunosuppression." This procedure amounts to fetal bone
marrow transplantation, by which successful intrauterine xenotransplanta-
tions (cells from one species to another) of fetal bone marrow have been
reported. 2 No recombinant DNA techniques are involved in these proce-
dures. If such studies could be done on humans with diseases that either
deprive children of normal hemoglobin (e.g., sickle cell disease) or produce
inadequate immune systems (e.g., severe combined immunodeficiency syn-
drome), then these diseases might be treated in the fetus after prenatal diag-
nosis by fetal cell transplants.
4) Transplantation of genetically corrected hepatocytes or fetal gene ther-
apy may be a source of treatment for some hereditary disorders, such as
some glycogen storage disorders, phenylketonuria, or hemophilia. Recent
research on sheep has shown promise for human studies. 3 Each of these
8. Rebecca H. Buckley, Fetal Thymus Transplantation for the Correction of Congenital
Absence of the Thymus (DiGeorge's Syndrome), in 2 CONSULTANTS TO THE ADVISORY COMM.
TO THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH, REPORT OF THE HUMAN FETAL
TISSUE TRANSPLANTATION RESEARCH PANEL D50, D53 (1988).
9. VICTOR A. McKusIcK, MENDELIAN INHERITANCE IN MAN: CATALOGS OF AUTO-
SOMAL DOMINANT, AUTOSOMAL RECESSIVE, AND X-LINKED PHENOTYPES, 927 (7th ed.
1986).
10. Kevin J. Lafferty, Diabetes Islet Cell Transplant Research: Basic Science, in 2 CON-
SULTANTS TO THE ADVISORY COMM. TO THE DIRECTOR, NATIONAL INSTITUTES OF
HEALTH, REPORT OF THE HUMAN FETAL TISSUE TRANSPLANTATION RESEARCH PANEL
D142, D143 (1988).
11. R.N. Slotnick et al., Stable Hematopoietic Chimerism Following In Utero Stem Cell
Transplantation, 43 AM. J. HUM. GENETICS A133 (1988).
12. Maria Michejda et al., Intrauterine Xenotransplantation of Fetal Bone Marrow: For-
mation of Hematopoietic Chimerism, 27 PEDIATRIC RES. 267A (1990).
13. M. Brandt et al., Targeting the Fetal or Newborn Liver by Hepatocellular Transplanta-
tion or Somatic Gene Therapy, 49 AM. J. HUM. GENETICS 435 (Supp. 1991).
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disorders can be diagnosed prenatally.
5) Parkinson's disease: Is there a genetic factor in Parkinsonism? One
hypothesis is that idiopathic Parkinsonism, which has a low-level familial
association and nonmendelian pattern of inheritance, may be caused by in-
heritance of mitochondrial genes."4 More research is needed to prove the
theory, but the importance of genetic studies to explain why dopamine cells
die in Parkinsonism is crucial. Neurosurgeons in Sweden and the United
States, using fetal neural cells known to be rich in dopamine, have attempted
dopamine replacement therapy in patients with Parkinson's disease. These
clinical results have been mixed.' 5
FTTR is closely related to the future of human gene therapy. First, each
attempt to treat any genetic disease is a link in the chain of a growing body
of knowledge which is the basis for human gene therapy experiments. In
FTTR, more understanding of gene expression in fetal cells will be gained, as
will the knowledge of how these cells interact with surrounding cells. This
knowledge will bear on future attempts at molecular intervention, which
may possibly result in a rejection phenomenon from transplant fetal cells.
Furthermore, progenitor cells obtained from the fetus after abortion can
now be cultured and proliferated for transplantation.' 6 After this step, a
potential exists to engineer cells genetically modelled after these original fe-
tal cells and cell lines to be used in treatment.
17
Human gene therapy is a sign of hope in a vast sea of human suffering due
to heredity. Gene therapy in the fetus would be a special expression of this
hope, since about twenty-two percent of newborn deaths in developed na-
tions are due to congenital malformations or genetic disorders.'" Approxi-
mately one-third of children admitted to pediatric units in Western nations
need treatment for the complications of genetic disorders, congenital defects,
or mental retardation.' 9 In addition, cancer is now best understood as a
14. William D. Parker et al., Abnormalities of the Electron Transport Chain in Ideopathic
Parkinson's Disease, 26 ANNALS NEUROLOGY 719, 719 (1989).
15. Olle Lindvall et al., Grafts of Fetal Dopamine Neurons Survive and Improve Motor
Function in Parkinson's Disease, 247 SC. 574, 574 (1990).
16. H. Fred Voss, Statement, in 2 CONSULTANTS TO THE ADVISORY COMM. TO THE
DIRECTOR, NATIONAL INSTITUTES OF HEALTH, REPORT OF THE HUMAN FETAL TISSUE
TRANSPLANTATION RESEARCH PANEL D252, D258-59 (1988).
17. Lars Olson, Parkinson's Disease Fetal Tissue Transplant Research Basic and Clinical
Studies, in 2 CONSULTANTS TO THE ADVISORY COMM. TO THE DIRECTOR, NATIONAL IN-
STITUTES OF HEALTH, REPORT OF THE HUMAN FETAL TISSUE TRANSPLANTATION RE-
SEARCH PANEL D219, D224 (1988).
18. See H. Galjaard, Early Diagnosis and Prevention of Genetic Disease, in ASPECTS OF
GENETIC DISEASE 1-15 (H. Galjaard ed., 1984).
19. John C. Fletcher, How Abortion Politics Stifles Science, WASH. POST, Feb. 5, 1989, at
D3; see also Robert L. Brent, The Magnitude of the Problem of Congenital Malformations, in
Abortion Politics, Science and Research Ethics
genetic disease.2°
Research with the human embryo is also a source of hope to relieve suffer-
ing. Because great emotional suffering accompanies infertility, many infer-
tile couples use technology, such as in vitro fertilization (IVF), as a last
resort. IVF creates the possibility of diagnosing genetic and chromosomal
abnormalities in the pre-implantation embryo. This step would clearly help
infertile couples who have experienced a high loss of abnormal human em-
bryos after implantation, and who may expect such losses to increase with
maternal age.21 As more women seek higher education, enter the work
force, and postpone earlier childbearing, a trend toward later pregnancies
and their higher chromosomal risks will increase.
The option of selective abortion following positive prenatal diagnosis also
carries negative emotional consequences. In fact, there is evidence of serious
emotional distress in both parents after a second trimester genetic abor-
22tion. Although advances in first trimester chorionic villus sampling have
reduced the level of such distress, one study shows that couples still suffer
emotionally after a first trimester genetic abortion. 23 Clearly, selective abor-
tion is not the best response to genetic disorders in the fetus; if the risks were
acceptable, therapy would be a better response. The punishing weight of
these burdens of heredity explain why a majority of Americans approve of
human gene therapy to treat particular children and to correct a gene "that
PREVENTION OF PHYSICAL AND MENTAL CONGENITAL DEFECTS PART A: THE SCOPE OF
THE PROBLEM 55 (Maurice Marois ed., 1985).
20. For recent articles that discuss cancer and genetics, see Jeff M. Hall et al., Linkage of
Early-Onset Familial Breast Cancer to Chromosome 17q21, 250 ScI. 1684 (1990); David Mal-
kin et al., Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and
Other Neoplasms, 250 ScI. 1233 (1990); Jean Marx, Genetic Defect Identified in Rare Cancer
Syndrome, 250 ScI. 1209 (1990).
21. S. Harlap et al., A Life Table of Spontaneous Abortions and the Effects of Age, Parity,
and Other Variables, in HUMAN EMBRYONIC AND FETAL DEATH 145, 149 (Ian H. Porter &
Ernest B. Hook eds., 1980); Dorothy Warburton, Reproductive Loss: How Much is Preventa-
ble?, 316 NEW ENG. J. MED. 158, 159 (1987).
22. For some psychological studies showing the emotional trauma associated with abor-
tions related to the prenatal detection of a genetic defect, see Bruce D. Blumberg et al., The
Psychological Sequelae ofAbortion Performed for a Genetic Indication, 122 AM. J. OBSTETRICS
GYNECOLOGY 799 (1975); P. Donnai et al., Attitudes of Patients After "Genetic" Termination
of Pregnancy, 282 BRIT. MED. J. 621 (1981); O.W. Jones et al., Parental Response to Mid-
Trimester Therapeutic Abortion Following Amniocentesis in 4 PRENATAL DIAGNOSIS 249
(1984); N.J. Leschot et al., Therapeutic Abortion on Genetic Indications: A Detailed Follow-Up
Study of 20 Patients, in ON PRENATAL DIAGNOSIS 96 (Marianne Verjaal & Nicolas J. Leschot
eds., 1982); Theresa Marteau et al., The Impact of Prenatal Screening and Diagnostic Testing
Upon the Cognitions, Emotions, and Behavior of Pregnant Women, 33 J. PSYCHOSOMATIC RES.
7 (1989).
23. Rita B. Black, A I and 6 Month Follow-Up of Prenatal Diagnosis Patients Who Lost
Pregnancies, 9 PRENATAL DIAGNOSIS 795, 795-96 (1989).
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would carry the disease to future generations."24 It is reasonable to suppose
that if a majority would approve preventive or germline gene therapy, it
would also approve FTTR. However, this question has never been studied
empirically.
B. Federal Moratorium on FTTR
What were the events that precipitated the moratorium on FTR in the
federal sector of science?
1. In 1986, neurosurgeons at the NIH Clinical Center designed a research
project to give patients with Parkinson's disease the choice of an adrenal
autotransplant or a fetal neural cell transplant. In keeping with Federal reg-
ulations,25 fetal tissue would be legally obtained from a local hospital's ob-
stetrics-gynecology service after consent by the woman and biological father
if available.
2. A Clinical Review Subpanel of the National Institute of Neurological
and Communicative Disorders and Stroke (NINCDS) approved the project
in September 1987. The Subpanel is an arm of the Clinical Center's human
subjects review system. Despite their anticipation of controversy, the high-
est authorities in NINCDS nonetheless gave their approval to the study.
NIH Director Dr. James Wyngaarden decided to seek higher departmental
review of FTTR. In October 1987, he asked the Assistant Secretary for
Health, Dr. Robert Windom, to review the FTTR project for a single patient
who had chosen the fetal transplant approach.
3. In March 1988, Dr. Windom withheld approval of the both proposed
experiment and "future experiments" in FTTR under federal auspices using
tissue from induced abortions. Since there was no Ethical Advisory Board
to which to refer the proposal, as required by federal regulations governing
such situations,26 he asked that NIH "convene one or more special outside
advisory committees that would examine comprehensively the use of human
fetal tissue from induced abortions for transplantation." '27 Dr. Windom sub-
mitted a list of ten questions concerning the morality and potential abuses of
FTTR for the consultant panel to consider.2"
4. The NIH panel convened in September 1988, and met three times, vot-
24. U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, NEW DEVELOPMENTS IN
BIOTECHNOLOGY: PUBLIC PERCEPTIONS OF BIOTECHNOLOGY, OTA-BP-BA-45, 73-74
(Washington D.C., U.S. Government Printing Office, 1987).
25. 45 C.F.R. § 46.209(d) (1991).
26. Id. § 46.204(d).
27. Memorandum from Robert E. Windom, M.D., Assistant Secretary for Health, to
James Wyngaarden, M.D., Director, National Institutes of Health 1 (Mar. 22, 1988) (on file
with author).
28. Id. at 1-2.
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ing eighteen to three on December 5, 1988 to approve federal support of
FTTR.29 Because it is of moral relevance that fetal tissue is derived from
induced abortion, the panel noted that it was acceptable public policy in this
pluralistic society to support FTTR. Additionally, the panel outlined princi-
ples to safeguard FTTR from abuses and ensure that the decision to abort
was well-separated from decisions to donate tissue for research.
5. Dr. Windom left office in December 1988, without acting on the NIH
report. The new HHS Secretary, Dr. Louis B. Sullivan, announced on No-
vember 2, 1989 that the moratorium on FTTR would be continued "indefi-
nitely. '' 30 His decision remains in effect today.
6. The term "indefinite" was chosen as a "legal term," according to con-
gressional testimony by Dr. James 0. Mason, Assistant Secretary for
Health. 3' The difference between "indefinite" and "permanent" was small,
according to Mason, but leaves some room for new information to permit
reconsideration.32 In addition, "indefinite" was chosen to lower the risks of
legal challenges to the extension of the moratorium.33 Both Representative
Ted Weiss (D-N.Y.) and the press cited a memorandum from HHS Counsel
Richard Riseberg, saying that the extension of the moratorium was on a
"shaky legal base" since it did not conform with the Administrative Proce-
dures Act.34 Under this Act, such decisions should be published in the Fed-
eral Register and then made the subject of rule-making. 35 Representative
Weiss appealed to Dr. Sullivan to reverse his decision. An undisclosed
source from the Public Health Service stated that they "have chosen to make
the moratorium indefinite rather than permanent [because] a permanent pro-
hibition of this research would require formal rulemaking procedures and
thus would require extensive formal public comment and would be rather
easily susceptible to litigation which could reverse this action."
36
7. Representative Henry Waxman (D-Cal.) introduced the Research Free-
29. See 1 CONSULTANTS TO THE ADVISORY COMM., supra note 1.
30. See Letter from Louis B. Sullivan, supra note 3, at 3.
31. Fetal Tissue Transplantation Research: Hearings Before the Subcomm. on Health and
the Environment of the House Comm. on Energy and Commerce, 101st Cong., 2d Sess. 80
(1990) [hereinafter Hearings] (statement of James 0. Mason, Assistant Secretary for Health,
U.S. Department of Health and Human Services).
32. Id.
33. Id.
34. Letter from Rep. Ted Weiss (D-N.Y.), Chairman, Human Resources and Intergov-
ernmental Relations Subcommittee of the House Committee on Government Operations, to
Louis W. Sullivan, M.D., Secretary, U.S. Dept. Health and Hum. Servs. (Jan. 26, 1990) (on file
with author); see also Philip J. Hilts, U.S. Aides See Shaky Legal Basis For Ban on Fetal Tissue
Research, N.Y. TIMEs, Jan. 30, 1990, at C6. The Administrative Procedures Act is located at
5 U.S.C. § 552 (1988 & Supp. 1992)
35. See 5 U.S.C. § 553 (1988).
36. Hilts, supra note 34, at C6.
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dom Act of 1990 in the 101st Congress. 7 The measure would nullify the
moratorium and prohibit officials in the executive branch from imposing
such a policy on NIH.38 It would authorize support for FTTR by or
through NIH once proposals have been reviewed by both local institutional
review boards and NIH on scientific and technical levels.39 FTTR can be
conducted in accordance with the recommendations of the NIH panel, un-
less an ethical advisory board convened by the HHS Secretary advises the
withholding of funds on ethical grounds.' This measure was approved by
the House of Representatives in July 1991, by a margin of 100 votes-16
short of the number needed to override a presidential veto. At this writing
the bill is before the Senate.4"
8. The American College of Obstetricians and Gynecologists and the
American Fertility Society established a national advisory board to monitor
FTTR and embryo research.4 2 This plan, proposed by scientific leaders
whose research is most affected by the separation of federal and private sup-
port, is similar to the establishment of a voluntary licensing authority to
oversee research with the human embryo. The plan was offered after the
government failed to take steps to establish standards for research on fetal
tissue and new reproductive technologies.43
C. Ethical Perspectives
Two ethical perspectives clash on the tissue of FTTR. One stresses an
imperative to relieve human suffering, the continuity of FTTR with the eth-
ics of organ transplants from cadavers, and the separability of the decision to
abort and the decision to donate fetal tissue. The other is based on an imper-
ative to protect fetal life and avoid encouraging abortion without regard to
loss of social and individual benefits due to a lack of federal support for
FTTR. Those who take the latter position accuse FTTR researchers of
moral complicity by benefiting from abortions. Supporters of the former po-
sition cannot ethically justify the lost opportunity to relieve suffering in those
who will worsen or die without attempted treatment. In this view, many of
the 1.5 million legal abortions in the United States each year are "wasted" in
37. H.R. 5456, 101st Cong., 2d Sess. (1990).
38. See id. § 203(a).
39. See id. § 101.
40. Id.
41. 137 CONG. REC. S15,708-10 (daily ed. Oct. 31, 1991).
42. Sally Squires, Groups Plan Advisory Board to Monitor Embryo, Fetal Tissue Research,
WASH. POST, Jan. 8, 1991, at A3.
43. Id. at 3.
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the face of the opportunities they present to learn and prevent great human
suffering.
Each position begins from premises and analogies that necessarily proceed
to different conclusions. Arguments in support of FTR begin with the
premise that either 1) elective abortions are morally acceptable or 2) some
abortions are morally justified and some are not, but in either case the deci-
sion to donate can be isolated from the decision to abort. Supporters of
FTTR stress that a woman's decision about abortion and the act of abortion
are distinct from her decision to donate tissue for FTTR and for other fetal
tissue research uses. One noted commentator, Dr. Thomas Murray, uses the
practice of organ transplantation as an analogy to distinguish between abor-
tion decisions and FTTR that is similar to a distinction made by society
between acts leading to deaths of persons who are sources of organs and the
use of organs for transplantation." According to Murray, the use of trans-
plants does not mean that society morally approves of the auto accidents or
suicides that result in the availability of organs.4" People have no moral
difficulty distinguishing the use of the organs from the causes that lead to
their availability. Murray and the majority of the NIH panel argue that a
distinction exists between abortion and FTTR, although they say that it is
"6morally relevant" that the source of most fetal tissue is elective abortion.
In fact, another scholar has written a comprehensive response to the moral
criticisms of FTTR and the NIH panel's recommendations, which are de-
scribed below."
On the other side of the issue, advocates begin from a premise that in-
duced abortions are evil almost without exception.4 7 This premise leads
them to a conclusion that FTTR is material cooperation with an evil so per-
vasive that any line-drawing disappears into a chasm of evil. They compare
FTTR researchers to bankers who ask no questions but accept large sums
for deposit from illegal drug transactions. Also, they link FTTR to Nazi
experiments on humans in concentration camps, aiming to evoke images of
44. Thomas H. Murray, Ethical Issues in Research on Human Fetal Tissue Transplanta-
tion, in 2 CONSULTANTS TO THE ADVISORY COMM. TO THE DIRECTOR, NATIONAL INSTI-
TUTES OF HEALTH, REPORT OF THE HUMAN FETAL TISSUE TRANSPLANTATION RESEARCH
PANEL D197, D199 (1988).
45. Id.
46. See generally James F. Childress, Ethics, Public Policy, and Human Fetal Tissue
Transplantation Research, I KENNEDY INST. ETHICS J. 93 (1991) (critically examining
charges that if funded by the federal government FTTR would involve complicity in the moral
evil of abortion, legitimate abortion practices, and provide incentives for abortions).
47. James Bopp, Jr. & James T. Burtchaell, Human Fetal Tissue Transplantation Panel:
Statement of Dissent, reprinted in CONSULTANTS TO THE ADVISORY COMM. TO THE DIREC-
TOR, NATIONAL INSTITUTES OF HEALTH, 1 REPORT OF THE HUMAN FETAL TISSUE TRANS-
PLANTATION RESEARCH PANEL 45-47 (1988).
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the epitome of evil. Three formal objections to FTTR are expressed: 1) wo-
men motivated to abort their fetuses cannot give an ethically valid informed
consent to donate tissue; 2) FTTR creates incentives for more abortions to
supply tissue; and 3) FTTR researchers participate in moral complicity with
the abortions that are the source of tissue.
In objecting to FTTR and supporting the moratorium on federal funding
of FTTR, Drs. Sullivan and Mason adopted the latter two of these three
reasons.4' Emphasizing the moral complicity with abortion, Mason wrote,
[T]he additional rationalization of directly advancing the cause of
human therapeutics cannot help but tilt some already vulnerable
women toward a decision to have an abortion.
[I]f just one additional fetus were lost because of the allure of
directly benefiting another life by the donation of fetal tissue, our
department would still be against federal funding.49
Until hearings convened before the Subcommittee on Health and the En-
vironment on April 2, 1990, the only HHS statements available on the sub-
ject were those by Drs. Sullivan and Mason.5° Dr. Mason, speaking at the
hearings, reviewed the reasoning for the moratorium: 1) The Administration
and Congress are opposed to funding activities that encourage or promote
abortion;5' 2) It is a fact-and of moral relevance-that human fetal tissue is
obtained from abortions;52 and 3) One "must accept the likelihood" that
permitting FTTR will increase the incidence of induced abortions across the
country53 because providing the additional "rationalization" of advancing
the cause of human therapeutics cannot help but tilt some already vulnerable
women toward a decision to have an abortion. 4
During his testimony, Dr. Mason was asked to explain the sources from
which he derived the evidence that FTTR would encourage abortions:
Mr. Waxman: The Federal Government has supported other forms
of fetal tissue research in cancer vaccines, developmental and
childhood medicine for over 30 years. Do you have any evidence
at all or any data that this has resulted in increased abortion?
Dr. Mason: No. That is what I have been trying to explain, Mr.
48. James 0. Mason, Fetal Tissue Transplantation Research, 5 Am. Soc'Y MICROBI-
OLOGY 304, 304 (1990); James 0. Mason, Should the Fetal Tissue Research Ban be Lifted?, 2 J.
NIH REs. 17, 17 (1990) [hereinafter Mason, Should the Ban be Lifted?].
49. Mason, Should the Ban be Lifted?, supra note 48, at 17-18.
50. See Hearings, supra note 31.
51. Id. at 72 (statement of Dr. Mason).
52. See id. at 71-72 (statement of Dr. Mason).
53. Id. at 72 (statement of Dr. Mason).
54. Id. at 74 (prepared statement of Dr. Mason).
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Chairman, that we have been doing fetal tissue research for 30
years, but this powerful inducement called fetal tissue transplanta-
tion with potential beneficial therapeutic effects is a new ball game.
We have no experience in that particular area, it is too new. Can
you imagine if fetal tissue transplantation proves to be successful,
that it is hyped in the media, the powerful inducement this be-
comes to a woman who is caught in that dilemma as to whether or
not to have an abortion and she knows that it may have a beneficial
effect for some other person?"
Some flaws mar the reasoning of advocates who would prohibit FTTR,
and one in particular affects the reasoning of the NIH panel. First, this
reasoning suffers from the logical fallacy of petitio principii or "begging the
question." In this instance, the premise that FITR will causally increase
abortions by motivating women in doubt about abortion to have one is as-
sumed to be true. Based on this unsupported premise, the public is asked to
accept as a significant conclusion, Le., "one must accept the likelihood," that
the potential for benefit in FTTR will persuade hesitant women toward
abortions.
No study exists on the cause and effect relationship between abortion and
FTTR. In fact, any study would have been anecdotal and retrospective
given the few cases to date. If a study could be done involving women in the
context of abortion counseling in which the hypothetical question "Would
you be more inclined to consider abortion if you knew that you could donate
tissue from the abortion that might even help someone in a desperate physi-
cal condition?" is asked, such a study would still be speculative, since the
subjects would not be in a real life situation.
In response to this assertion, the NIH panel stated, "[R]esearch using fetal
tissue has been conducted and publicized for over 30 years. There is no
evidence that this use of fetal tissue for research has had a material effect on
the reasons for seeking an abortion in the past."56 The evidence available to
the panel when making this statement was the historical record, the litera-
ture, and the experience to date in Sweden's use of FTTR. Directed dona-
tions occur when donors select recipients in advance. The panel noted that
although Sweden now prohibits this practice with fetal tissue, there is no
reported evidence that their prior experience with donations of fetal tissue
for basic research, such as growing cell cultures to test vaccines, was an
inducement to abortion by resolving ambivalence. Nonetheless, the impor-
tant point remains that the question of the psychological effects of donating
55. Id. at 77.
56. 1 CONSULTANTS TO THE ADVISORY COMM., supra note 1, at 3.
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fetal tissue has not been studied, even in the context of donating it for basic
research or FTTR.
To reduce chances that abortion would be induced or pressured by the
prospect of donation, the panel recommended obtaining consent for FTTR
only after a woman decides to abort. The panel also recommended prohibit-
ing directed donations. There are no studies investigating whether the deci-
sion to abort and the decision to donate are, in fact, separable or kept
separate by researchers and subjects in the decision-making process. Secre-
tary Sullivan stated that he doubted whether a line could be successfully
maintained between the decision to abort and the decision to donate.57 He
argued that women would need to be consulted about the use of fetal tissue
before "the abortion is actually performed" because of the need to use the
tissue promptly.58 He claimed that need would "influence the decision[-
]making process."" 9 Thus, the question becomes whether current requests
to use fetal tissue for research after abortion influence the decision-making
process to have an abortion. The need for data creates an important oppor-
tunity for creative social science and psychological research to provide valu-
able contributions to research ethics.
A second flaw in the reasoning of Mason and other defenders of the mora-
torium is an omission to condemn all research with fetal tissue obtained
from induced abortion. If moral complicity with abortion is so evil as to halt
federal support of possible lifesaving therapy to prevent the loss of one addi-
tional fetus by abortion, then why does the condemnation not apply to all
uses of fetal tissue after induced abortion, including all research with fetal
tissue funded by HHS through the NIH?
Dr. Mason addresses this question less in the context of the argument of
cooperation with the evil of abortion than in consequential terms that con-
strue FTTR as a "powerful inducement" to abortion and a technique that, if
effective, will require a large supply of fetal tissue. As he testified:
Mr. Waxman: We do have these other fetal research activities go-
ing on which we have had for 30 years. Your ban does not address
any of these other areas of fetal tissue research. Why is that? How
do you justify banning transplant research alone. What do you say
to the Parkinson's patients who think you are treating cancer pa-
tients more fairly?
Dr. Mason: Mr. Chairman, a number of people have favored ex-
tending the moratorium to include all fetal research. We rejected
that for a number of reasons. First of all, in the context of quantifi-
57. See Letter from Louis B. Sullivan, supra note 3, at 1.
58. Id. at 2.
59. Id.
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cation of inducement for abortion, the direct benefits another
human might receive from fetal tissue transplantation ... would
tip the scale to a decision already the result of deep soul searching.
The inducement here is high. It is like an organ transplant induce-
ment is much higher than donating a cadaver to a medical school
for dissection. General research is not as dramatic as direct thera-
peutic effect upon another human being.
The second [reason] . . . is the concept of tissue requirements.
For polio, for example, all of the . . research and therapeutics
were carried out on stable cell lines derived from three fetuses. In
other words, whether the fetus was derived from a spontaneous
abortion or however you started with the first fetus, you didn't
have to go back and derive further fetal tissue because it was a
stable cell line, while with human fetal tissue transplantation from
induced abortions, right now, with regard to Parkinson's disease,
they had to use the tissue from-what is it?-two to four fetuses
for one patient, and each time you have to go back to a fresh sup-
ply of fetal tissue.
• . . So inducement and the quantification of the supply were
both powerful reasons in our deciding that we should not continue
to support fetal tissue research .... 60
This argument invalidates the premise that abortion is so evil that even
one abortion induced by research would be wrong. What about all the past
and future abortions that serve basic research involving fetal tissue? Dr.
Mason invokes the polio example alone, but basic fetal tissue research con-
tinues to be done with fetal material from new abortions. To be consistent
with his premise, there should be no abortion-derived research.
Dr. Sullivan's observation that FTTR can be done with private funding
gives rise to a third flaw in reasoning, L e., he bases morality on the source of
funds rather than on principles, beliefs of what is right or wrong, and conse-
quences. According to his reasoning, unless there are different moralities for
the public and private sector, FTTR deserves blame however supported.
The comment that FTTR can be done with private funds undermines the
moral position that Dr. Sullivan tries to take.
There is a clear need for a social and psychological study conducted with
a hypothesis that FTTR either does or does not have the effects presumed by
the HHS Secretary or the NIH panel. The study could be prospective and
accomplished through interviews of a large sample of women in the context
of abortion counseling. It is a fact that a moratorium on FTTR-in the face
60. See Hearings, supra note 31, at 79.
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of great human suffering-is being extended on the basis of an unproven,
speculative premise. Without data to resolve the question of undue induce-
ment, the moral burden on those opposed to FTTR is very great.
Another option in obviating the moral concern of FTTR opponents is to
secure fetal tissue from spontaneous abortions, as proposed by Thorne and
Michejda.61 They argue that the number (possibly 750,000) of such events
occurring in U.S. hospitals justifies organized preparedness to use these tis-
sues rather than those from elective abortions. They do not address the
problem of the large number of such pregnancy losses due to chromosomal
malformations or intrauterine infections. Either of these conditions is reason
for not using these tissues. However, tissues from some spontaneous abor-
tions would be useable and this option is not prohibited by the moratorium.
II. FTTR IN HISTORICAL CONTEXT: FETAL AND EMBRYO RESEARCH
Current federal policy on FITR cannot be understood apart from the his-
tory of federal policy on fetal and human embryo research in the period from
1974 to the present. The history of this policy reveals a radical change from
a policy of restriction requiring national review for due process purposes to
prevent exploitation of the fetus and embryo in research to a policy separat-
ing private from federal support and withdrawing the latter due to associa-
tion with abortion or embryo loss.6 2 Public consideration of these issues
arose in the 1970s when federal policy was that the public/private partner-
ship in science was intact and that a national forum in which to debate im-
portant ethical issues in biomedical science was a priority for the well-being
of the nation and the public interest. In this period, "bridges" rather than
"walls" were built between the public and private sector to increase commu-
nication and resolve conflicts.
Fetal research in the abortion context was originally debated in 1974 by
the National Commission for the Protection of Human Subjects of Biomedi-
cal and Behavioral Research following the appointment of the Commission
by a Congress concerned that, in the wake of Roe v. Wade,63 fetuses would
be exploited for research after abortions." Subsequent federal regulation
65
61. See Emanuel D. Thorne & Maria Michejda, Fetal Tissue From Spontaneous Abortions:
A New Alternative For Transplantation Research?, 4 FETAL THERAPY 37 (1989).
62. John C. Fletcher, Restriction and Suppression: Fetal and Embryo Research: 1974-1990,
Proceedings of Symposium on the Beginnings of Human Life, University of Iowa, (Nov. 1990)
(forthcoming 1992).
63. 410 U.S. 113 (1973).
64. NATIONAL COMM'N FOR THE PROTECTION OF HUM. SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH. REPORT AND RECOMMENDATIONS: RESEARCH ON THE FETUS 61-
88 (Washington, D.C., U.S. Government Printing Office, DHEW Publication No (OS) 76-127
(1975)).
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adopted the Commission's recommendations to restrict fetal research in the
context of abortion and especially to limit investigative fetal research with
federal funds to a "minimal risk" level, which "means that the risks of harm
anticipated in the proposed research are not greater, considering probability
and magnitude, than those ordinarily encountered in daily life or during the
performance of routine physical or psychological examinations or tests."
66
The regulations also provided that if valuable knowledge was impossible
by means other than fetal research, minimal risk could be exceeded if an
Ethical Advisory Board (EAB) advised the Secretary of HHS to use a secre-
tarial "waiver" of the risk standard. 67 No EAB has existed to advise the
Secretary since 1979. No research proposals for fetal research in the context
of abortion have been submitted to the NIH since 1979, when a trial of fetos-
copy to diagnose sickle cell disease was recommended to Secretary Califano
by an EAB. 6' Historically, federal funds have supported few fetal studies of
any type, including fetal therapy.
69
Ethical understanding of fetal research in the context of abortion has seri-
ously shifted among public officials since the 1970s. Albert Jonsen, a mem-
ber of the National Commission, wrote that the majority of commissioners
in 1974 who favored fetal research in the context of abortion likened the
activity to phase I cancer studies, iLe., both fetal research and phase I cancer
research are morally problematic. 70 The cancer patient is going to die. Soci-
ety permits phase I cancer trials largely to study drug toxicity. Lipsett ar-
gued that if phase I trials are to be ethical, a probability of benefit based on
animal research is required.7 1 In reality, the probability of benefit from
phase I trials is very small. However, some phase I studies involving chil-
dren are financed under federal auspices, and these trials are conducted on
living children when no data is available from experience with adults.72
Children cannot consent because of their minority, and their parents must
65. 45 C.F.R. § 46.205-.211 (1991).
66. 45 C.F.R. § 46.102(i) (1991).
67. 45 C.F.R. § 46.211 (1991).
68. Ezra C. Davidson, Jr., Statement, in 2 CONSULTANTS TO THE ADVISORY COMM. TO
THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH, REPORT OF THE HUMAN FETAL TIS-
SUE TRANSPLANTATION RESEARCH PANEL D82, D84, D87 (1988).
69. John C. Fletcher & Joseph D. Schulman, Fetal Research: The State of The Question,
HASTINGS CENTER REP., Apr. 1985, at 6, 6.
70. Albert R. Jonsen, Transplantation of Fetal Tissue: An Ethicist's Viewpoint, 36
CLINICAL RES. 215, 218 (1988).
71. Mortimer B. Lipsett, On The Nature'And Ethics of Phase I Trials, 248 JAMA 941,
941 (1982).
72. Richard S. Ungerleider & Susan S. Ellenberg, Cancer Clinical Trials: Design, Conduct,
Analysis, and Reporting, in PRINCIPLES AND PRAC. OF PEDIATRIC ONCOLOGY 275, 277
(Philip A. Pizzo & David G. Poplack eds., 1989).
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give permission for such research after it has been approved by an Institu-
tional Review Board (IRB) under rules for research exceeding minimal
risk."3 Jonsen stated that the commissioners reasoned along these lines to
justify fetal research.
Jonsen used another analogy to describe the views of opponents, namely
that fetal research in the context of abortion was like research on prisoners
condemned to die. This ethical understanding apparently predominates to-
day among public officials. Under present federal policy, reinforced by a
congressional ban on investigative fetal research, the secretarial waiver can-
not be used. The thrust of current research policy is that fetuses in the con-
text of abortion have a higher priority for social protection than living
children. Should society permit research74 with greater than minimal risks
with living children 75 and deny research with the first trimester fetus in the
context of abortion? Present federal policy encourages this moral
contradiction.
The moral contradictions involved in withholding federal support for em-
bryo research are even sharper. The study of cells and genes in human em-
bryos may add discoveries that will directly affect treatment of genetic
disorders and cancer. Yet, under federal regulations in effect since 1975, no
federal funds may be spent on embryo research until a chartered EAB ad-
vises the Secretary that it would be ethical to do so.76 An EAB so advised
Secretary Califano in 1979,77 but its term was then allowed to lapse, never to
be rechartered. No subsequent HHS Secretary has ever approved the EAB
report. The losses to diagnosis and treatment of infertility and genetic and
other diseases are significant because no studies involving in vitro fertiliza-
tion (IVF) can proceed to scientific and technical review at the NIH without
EAB approval.78
Among these losses are advances in cancer research. Scientists now have
the tools to understand the origins of many cancers and to apply this knowl-
edge to cancer treatment. As long ago as 1983, Dr. G. Barry Pierce re-
viewed embryonic regulation of some types of cancer and the role of this
73. John C. Fletcher et al., Ethical Considerations in Pediatric Oncology, in PRINCIPLES
AND PRAC. OF PEDIATRIC ONCOLOGY 309, 312 (Philip A. Pizzo & David G. Poplack eds.,
1989)
74. 45 C.F.R. § 46.306 (1991).
75. 45 C.F.R. § 46.406 (1991).
76. 45 C.F.R. § 46.204(d) (1991).
77. See ETHICS ADVISORY BOARD: REPORT AND CONCLUSIONS: HEW SUPPORT OF RE-
SEARCH INVOLVING HUMAN IN VITRO FERTILIZATION AND EMBRYO TRANSFER (May 4,
1979).
78. See supra note 69 and accompanying text.
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understanding for therapy.7 9 Pierce began with the knowledge that embry-
onic fields determine the changes from benign to malignant cells as in testic-
ular carcinoma. He proposed that it is possible that "an embryonic field
capable of regulating every carcinoma" exists.80 Studies of embryos might
lead to purposeful induction of changes in cells from malignant to benign.
Finally, physicians might substitute ways to induce malignant cells to
change as a replacement for cytotoxic agents in cancer treatment.
Other cancer experts also see the value of embryo studies. Adamson's re-
view of the role of oncogenes in development stressed the need to study cells
in the entire period of gestation, e.g., embryonic, fetal, and placental."1 Re-
viewing molecular and cellular biology in pediatric cancer, Israel writes,
"With great success, it has become possible to identify the chemical and
biological agents that can transform normal cells to malignant ones... [and
that] dramatic advances in cellular biology and recombinant DNA technol-
ogy ... [have] combined to focus attention on cancer as a genetic disorder
t982
If cancer is a genetic disorder, then hope for diagnosis and treatment is
realistic given the tools of modern molecular biology. In this vein, the first
true experiment involving rDNA in humans was a diagnostic study in can-
cer patients that teamed oncologists at NIH with a group studying experi-
mental human gene therapy. 3 This experiment has created great hope for
cancer treatment using genetic techniques. Physicians must, however, learn
how to use these techniques, especially in the human embryo in which many
cancers begin. It is starkly contradictory that federal policy encourages can-
cer drug studies in children, including phase I trials that can cause harm and
even death from toxicity to a child with cancer,8 4 and yet prohibits support
of embryo studies to discover how such cancers might begin.
The same contradictions are found in the withholding of support from
basic research using embryonic cells for genetic research. Such research
may reveal the origins of classical mendelian genetic disorders. Caskey, a
geneticist long interested in genetic diagnosis and treatment, states that the
natural history of genetic disorders will be vastly improved "if we study em-
79. See G. Barry Pierce, The Cancer Cell and its Control by the Embryo, 113 AM. J.
PATHOLOGY 117, 117 (1983).
80. Id. at 123.
81. Eileen D. Adamson, Oncogenes in Development, 99 DEV. 449, 449 (1987).
82. Mark A. Israel, Molecular and Cellular Biology of Pediatric Malignancies, in PRINCI-
PLES AND PRACTICE OF PEDIATRIC ONCOLOGY 39, 39 (Philip A. Pizzo & David G. Poplack
eds., 1989).
83. See Leslie Roberts, Human Gene Transfer Test Approved, 243 ScI. 473, 473 (1989).
84. Wayne L. Furman et al., Mortality in Pediatric Phase I Clinical Trials, 81 J. NAT'L
CANCER INST. 1193, 1193-94 (1989).
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bryonic cells in early development to learn how genetic disease occurs at all.
We must learn how and when genes that cause diseases 'turn on and off' as
the embryo develops.""5 In human genetics this discovery is comparable in
significance to Pasteur's discovery of the bacteriological origins of many
common diseases. However, approaches to prevention and treatment on the
molecular level are infinitely more complex than pasteurization or vaccina-
tion. Braude and others in the United Kingdom have learned that human
gene expression first occurs between the four- and eight-cell stages of pre-
embryo development.8 6 Do any harmful genes begin to express before im-
plantation? Can these expressions be detected by new techniques like
polymerase chain reaction, from which the smallest amounts of DNA can be
amplified many times for,testing purposes? If so, then genetic diseases as
well as chromosomal disorders could be diagnosed in the preimplantation
embryo, thus enabling the avoidance of implantation of an affected embryo
by selection.
Finally, another contradiction arises with respect to federal support of the
Human Genome Project, which proposes to map the location of genes on
human chromosomes by the year 2005.87 This mapping project is on a colli-
sion course with federal policy not to support fetal and embryo research.
Congress and the public have embraced the Human Genome Project largely
on the basis of the clinical benefits it will bring. How can these benefits come
without support of the research required? Until obstacles to clinical re-
search are removed, these benefits will be long delayed or impossible to
attain.
III. A WALL OF SEPARATION: PERMANENT OR TEMPORARY?
A growing wall of separation prevents federal research or review activities
in public health and science linked to abortion or embryo research. The wall
began in 1977-78, not in research but in medical services, when Congress
separated the federal share of the costs of elective abortions for Medicaid-
eligible women from other forms of state, local, and private funding. 8 The
Hyde Amendment,8 9 named for its sponsor, Representative Henry Hyde (R-
85. Fletcher, supra note 19, at D3.
86. See Peter Braude et al., Human Gene Expression First Occurs Between the Four- and
Eight-Cell Stages of Preimplantation Development, 332 NATURE 459, 459-61 (1988).
87. NATIONAL INSTITUTES OF HEALTH, U.S. DEP'T OF HEALTH AND HUM. SERVS.,
THE HUMAN GENOME PROJECT: NEW TOOLS FOR TOMORROW'S HEALTH RESEARCH 4
(1991).
88. ALAN GUTMACHER INST., ABORTIONS AND THE POOR: PRIVATE MORALITY, PUB-
LIC RESPONSIBILITY 6 (1979).
89. 122 CONG. REC. H20,410 (daily ed. June 24, 1976) (statement of Rep. Hyde). The
Hyde Amendment became law in 1976. Departments of Labor and Health, Education, and
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Ill.), limits federal funding only to cases of reported rape and incest and
when two physicians attest that continuation of the pregnancy will result in
severe and long-lasting damage to the woman's physical health. New incre-
ments to the wall have been added. Separating federal and private support
for activities that bear directly on fetal diagnosis and therapy affect: 1) re-
search involving the human embryo and fetus in utero from implantation to
delivery or the human fetus ex utero after induced abortion; 2) the pre-im-
plantation human embryo after IVF; and 3) in FTTR, as this Article has
shown. Table 1 summarizes the scope of research activities that are
blocked-the latter three activities--or hampered-the first.
The wall also prevents any federal funding of clinical research and devel-
opment of the drug RU-486, which acts as an abortifacient. This drug is a
possible treatment of Cushing syndrome, breast cancer, and other disorders.
While NIH is able to do therapeutic research with RU-486, an FDA alert
prevents the importation of RU-486 for use as an abortifacient. Although
trials in other nations demonstrate its efficacy for this purpose, abortion op-
ponents in Congress influenced the FDA to prohibit its use in the United
States.9 One does not have to be an opponent of abortion and embryo loss
to desire a wall of separation between public and private funding. This de-
sire may stem from hope for social harmony, similar to reasons that led to
separation of private support of religion from the government's establish-
ment and support of it. As noted above, Thomas Jefferson first used the
phrase "wall of separation" to describe the effect on religions of the first
clause of the First Amendment.9 In that context, the state is benignly neu-
tral toward religion, not giving privilege or support to the activities of reli-
gious groups, nor making any law to prohibit the free exercise of religion by
citizens. Just as the purpose of the First Amendment is ameliorative, i.e., to
prevent social conflict and special privilege stemming from state partiality in
religious matters, so might a wall preventing federal involvement in fetal and
embryo research be seen as peacemaking in the long run. In this vein, John
Courtney Murray, a preeminent twentieth century Catholic scholar on
church and state, stated that commitment to the First Amendment was a
moral commitment, the equivalent to "articles of peace in a pluralist soci-
ety."92 In the abortion controversy, the sheer divisiveness of the issues that
Welfare Appropriations Act of 1977, Pub. L. 94-439, § 209, 90 Stat. 1418, 1434. The Amend-
ment went into effect in 1980, after the Supreme Court declared its constitutionality. Harris v.
McRae, 448 U.S. 297, 326 (1980).
90. See Joyce Price, Fear of Pro-Lifers Kept Abortion-Pill Tests From US., WASH. TIMES,
Dec. 6, 1991, at A3.
91. See supra note 5.
92. JOHN C. MURRAY, WE HOLD THESE TRUTHS: CATHOLIC REFLECTIONS ON THE
AMERICAN PROPOSITION 85 (Image Books 1964) (1960).
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TABLE 1. FEDERAL RESEARCH ACTIVITIES BLOCKED OR HAMPERED
1) Experimental somatic cell gene therapy in diagnosed and affected fetuses
to be delivered.*
2) Fetal tissue transplant research with tissue or cells from early induced or
spontaneous abortions** for treatment of diseases with genetic causes in
liveborn affected individuals (Parkinson's disease, diabetes mellitus - Type
I, diGeorge syndrome, and diseases that destroy normal hemoglobin or
produce inadequate immune systems). Treatment in fetuses with these or
similar conditions is also possible.***
3) Basic DNA research involving fetal tissues or embryonic cells after early
induced abortion to understand gene expression and understand the natural
history of genetic diseases including some familial cancers; such research
could facilitate development of gene therapy by rDNA or by drugs.
4) Research on diagnosis of genetic disease in the human preimplantation
embryo to learn if embryo selection can prevent genetic disease, avoid
selective abortion, and perhaps open a way to germ-line gene therapy.****
* This activity is seen as "hampered" and the remaining three as "blocked." It is uncertain
whether fetal gene therapy experiments can be approved by the Human Gene Therapy
Subcommittee and the Recombinant Advisory Committee alone. Will a recommendation also
be necessary from an Ethics Advisory Board (EAB) required by Federal regulation but
unchartered since 1980? There is precedent for review of Federally supported fetal research by
an EAB. Technically, a fetal gene therapy project would not require any use of the "secretarial
waiver" of minimal risk so problematic in investigative fetal research in the context of elective
abortion. Fetal gene therapy is therapeutic in intent, designed to "meet the health needs of...
the particular fetus 45 C.F.R. § 46.206 (1991). However, the Secretary of HHS, can request
advice from an EAB about ethical issues raised by individual applications or proposals. Id.
§ 46.204(b). Reinstating an EAB is controversial due to links with fetal research.
** Federally funded therapeutic research with fetal cells after spontaneous abortion would not
be precluded by the present moratorium. However, there have been no proposals submitted to
the NIH. Why? The answer may lie in the rate of infection and chromosomal abnormalities
in spontaneous abortions. Another reason may be due to the absence of an Ethics Advisory
Board to which to refer proposals. We must presume that there is a strong perception of an
obstacle in the minds of investigators even though no obstacle exists.
*** For relevant discussions to these points, see supra notes 8-14 and Table 2.
**** John C. Fletcher & W.H. Anderson, Human Gene Therapy: A New Stage of Debate, L.
MED. & HEALTH CARE (forthcoming 1992).
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arise from religious and ethical beliefs seems irreconcilable. In this light,
some might view a permanent wall of separation as fitting.
Another reason to desire separation between public and private support of
research is recognition of the failure of government, under the pressures of
abortion politics, to be a fair and impartial source of conflict resolution in
research ethics.9" Rather than be a wise patron of debate in this area, the
government has become more than an active participant in the debate since
it has used political authority to bring closure. The government has been
unwilling or unable to provide a forum to study, debate, and resolve these
issues. For example, Congress created a Congressional Biomedical Ethics
Board in 1985 with a mandate to examine the power given to the Secretary
of HHS to waive the minimal risk requirement in fetal research.94 This
Board was given the mandate to examine issues related to research in human
genetics. 9" However, the Board collapsed in 1989, unable to function due to
conflicts about the abortion issue. 96 Due to abortion politics, there is now no
official national forum within which to consider these questions. However,
neither peacemaking nor loss of confidence in government are reasons that
outweigh four ethical and public policy arguments to dismantle this wall.97
One of the primary ends of medicine-the relief of human suffering-gives
rise to the first of the reasons to dismantle the wall. This obligation, also
grounded in social ethics, must not be set aside in the research arena unless
the means or ends of research violate ethical principles or rights cherished by
a wide majority in society. A minority opposes embryo and fetal research on
ethical grounds. However, if the cause is ethically justified, the will of a
minority ought to be overruled. The obligation to relieve human suffering
continues to be violated by vast deprivation in resources, knowledge, and
personnel caused by federal disengagement from research and therapy in
these areas. As the population ages and as the value of each healthy child
continues to increase, these benefits will be more difficult to deny. The mod-
ern state's dependence on science, especially in human reproduction, is too
deep and beneficial to reverse permanently. These benefits are being stunted
93. Myron Genel & Sarah Carr, The Politics of Abortion are Stifling Promising Areas of
Research, CHRON. HIGHER EDUC., Nov. 15, 1989, at 56.
94. See Philip J. Hill, Abortion Debate Clouds Research on Fetal Tissue, N.Y. TIMES, Oct.
16, 1989, at A19.
95. Id.
96. Id.
97. See generally Kenneth J. Ryan, Fetal Tissue Transplantation Research: Against The
Moratorium, 56 ASM NEWS 304 (1990) (maintaining that the moratorium on federal funding
of transplantation research impedes progress in relieving human suffering, discourages the sci-
entific community, creates a moral vacuum on the issue it is supposed to address, and cedes
progress in medicine and science to other countries).
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in the United States. However, if experience in the United States is compa-
rable to that in the United Kingdom, clinical success will create a better
climate to restore a federalprivate sector partnership in the whole domain of
science. As mentioned above, the project to map the human genome will
create more pressure for support of clinical research to apply the knowledge
gained. The Research Freedom Act is the first step in that process.
The second reason arises from a need to redress serious violations of aca-
demic and scientific freedom in the federal sector of science. Federal regula-
tions that require one or more Ethical Advisory Boards have been flaunted
openly by the last two Administrations. Due to this evasion of the law, no
applications are being received at the NIH for support of embryo or fetal
research. This forum must be restored to enable scientists to apply for fund-
ing under federal law and to have ethical disputes about their proposals
properly discussed and negotiated. It is this author's opinion that the scien-
tific and academic freedom of neurosurgeons at the NIH's Clinical Center to
do FTTR has been violated by HHS officials. Many other scientists have
been blocked from applying to the NIH for support of fetal or embryo re-
search. Moreover, an opportunity for scientists to petition for redress of
these grievances, guaranteed by the Administrative Procedure Act, was
evaded when HHS officials chose not to conduct legally required hearings
and rule-making for extending a moratorium on FTTR. If the argument to
this point in this Article has been persuasive, it should lead to the conclusion
that one of the greatest harms done to science in the federal sector has been
not only lack of support but also the manipulation and elimination of the
due processes created in the 1970s for resolving ethical and scientific dis-
putes in proposed clinical research. Those persuaded by the argument must
work to reverse the situation and to restore these national bridges of commu-
nication and negotiation, lest other legitimate areas of science be separated
and functionally suppressed. If the United States is to support a federal sec-
tor of science, it should include every legitimate scientific area including re-
search activities with the fetus and embryo.
A third reason to dismantle the wall is that the ban on FTTR and other
restrictions on fetal and embryo research clearly violate the imperatives of
distributive justice in clinical research. The ethics of research require that its
benefits be shared equitably with those who can clinically benefit the most
from the knowledge to be gained. Neither embryo research, clinical trials of
FTTR, randomized trials of fetal diagnosis, nor fetal therapy9 8 have yet oc-
curred with federal support; therefore, the populations most affected by
98. The National Institute of Child Health and Human Development has recently decided
to fund a clinical trial of fetal surgery for diaphragmatic hernia.
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blockage of this research have been unjustly treated. Since tax proceeds are
used to support federal research, Americans and their descendants who are
most adversely affected by the withdrawal of federal support for fetal and
embryo research are unfairly taxed. As a result of these practices, the bur-
dens of research are unfairly distributed to the private sector and other
nations.
A final reason was given by the physician-investigators who have created a
new national body99 to monitor FTTR and embryo research. Dr. Kenneth
Ryan, one of their leaders, noted a "moral vacuum" for the oversight of
FTTR and embryo research which, if unfilled, will lead to premature and
untested standards for clinical practice. This has already occurred with in
vitro fertilization and other methods of assisted reproduction. Scientists and
their colleagues in ethics, law, and other disciplines need to support this new
group in its formative period and activities. However, they also must not
lose sight of a goal to dismantle, by legal means, a wall in the federal sector
that impedes the goal of medicine and the progress of science and that un-
justly deprives millions of Americans and their children of knowledge that
will lead to better health.
IV. RESOURCES IN RESEARCH ETHICS: ADEQUACY OF THE BELMONT
REPORT
There is no legal or constitutional question about the authority of the Ad-
ministration or Congress to deny funds or NIH scientific peer review to
these activities. "° No constitutional right for research funding exists. The
U.S. Supreme Court has ruled that government may select to promote one
or more interests above a constitutionally protected activity, such as, in this
case, the protection of the interests of fetuses and embryos above the unim-
peded freedom of research understood as free speech.°10 The major goal of
this Article is to question the ethical and public policy wisdom of a wall of
separation. Is a separation similar to that which exists between organized
religion and the state necessary between public and private support of fetal
and embryo research? The answer is that while religion and government
need to be vigorously separated, biomedical research and government do
99. See supra note 42 and accompanying text.
100. This Article does, however, raise two legal questions for examination: 1) Have HHS
officials duly observed the requirements of the Administrative Procedure Act in continuing the
moratorium on FTTR "indefinitely" with no public notice or hearings?; and 2) Have HHS
officials violated Federal regulations by avoiding to recharter an EAB? See 45 C.F.R.
§ 46.204(b) (1990).
101. See John A. Robertson, The Scientist's Right to Research: A Constitutional Analysis,
51 S. CAL. L. REV. 1203, 1209 (1978).
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not. Does the moral issue of research arise from its source of funding? If the
answer to this question is obvious, then political and scientific leaders need
to turn to the task of dismantling a wall which has been erected in the wrong
place. In the meantime, many health benefits have already been lost, as doc-
umented by the Institute of Medicine.'° 2 There have already been extremely
serious consequences to the limited quality and quantity of U.S. biomedical
research in treatment of infertility, fetal diagnosis, maternal-fetal medicine,
reproductive genetics, and cancer.
The foremost reason to dismantle the wall is a moral obligation to learn if
paths of research will lead to therapies for fetuses and live-born persons
which would relieve great suffering and prevent premature death. This obli-
gation falls equally on the public and private sector. Therapy, the end of
these research activities, is virtually nonobjectionable. As mentioned above,
the means of such research should also be ethically acceptable to the major-
ity. The issue of means can only be worked out in a public forum with full
debate about the moral significance of disputed means. The most objectiona-
ble actions of public officials, in terms of this requirement, are to dismantle
or abandon all duly authorized public forums for such bioethical and scien-
tific debate-except the Congressional forum. No national bioethics forum
exists in the United States today to address the agenda in research ethics.
The United States must begin anew in the 1990s to restore the progress in
research ethics made in the 1970s. To reinvigorate this arrested process, we
should enlarge our vision of goals for research, the ethical principles that
structure and pattern research activities, and the tasks that must be done in
prior group review of specific projects.
What are the major ethical resources for the particular tasks of learning
through biomedical and behavioral research? The Belmont Report' 0 3 was
an early consensus document on the ethics of biomedical research in the
United States. It set forth three major ethical principles to guide research
with human subjects, including fetuses. The principles include respect for
persons, beneficence, and justice.'o An argument can be made however that
a more complex set of five ethical principles, outlined in Table 2, is required
to guide the scope and practices of biomedical research.
The Belmont Report interpreted the principle of beneficence to contain
within it the imperatives to avoid and prevent harm. 105 Would it not serve
ethical analysis better to use the principle of beneficence only as the frame-
102. See SUZANNE WYMELENBERG, SCIENCE AND BABIES: PRIVATE DECISIONS, PUBLIC
DILEMMAS 147-49 (1990).
103. BELMONT REPORT, supra note 7, at 4-10.
104. Id.
105. Id. at 6.
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TABLE 2. ETHICAL PRINCIPLES FOR PRACTICE AND RESEARCH
RESPECT FOR PERSONS: The duty to respect the self-determination and
choices of autonomous persons, as well as to protect persons with
diminished autonomy (e.g., young children, mentally retarded persons, and
those with other mental impairments).
BENEFICENCE: The obligation to secure the well-being of persons by acting
positively on their behalf and, moreover, to maximize the benefits that can
be attained.
NONMALEFICENCE: The obligation to minimize harm to persons and,
wherever possible, to remove the causes of harm altogether.
PROPORTIONALITY: The duty, when taking actions involving risks of harm,
to so balance risks and benefits that actions have the greatest chance to result
in the least harm and the most benefit to persons directly involved.
JUSTICE: The obligation to distribute benefits and burdens fairly, to treat
equals equally, and to give reasons for differential treatment based on widely
accepted criteria for just ways to distribute benefits and burdens.
Material adapted from: NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS
OF BIOMEDICAL AND BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL
PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH
(1983); TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS
121 (3d ed. 1989).
work for maximizing the benefits of research? It would make sense to turn
to a clearer principle, nonmaleficence, to guide the imperative to avoid and
prevent harm. The principle of nonmaleficence, prominent in the history of
biomedical ethics, 1°6 is relevant to ethical issues caused by the necessity of
taking risks and doing harm by research.
According to Belmont, beneficence was the primary source by which as-
sessments of risks and benefits to human subjects and society were to be
made."17 The principle of proportionality, however, provides more direct
and cogent guidance for riskbenefit assessments, one of the most difficult
tasks in research ethics especially when the fetus is involved. When on the
brink of research justified by a goal of seeking a remedy for great suffering
and yet unattainable except by doing some harm, researchers need guidance
on the question of how much harm is proportionate to the goal sought. Do
the expected benefits outweigh the risks that can be reasonably expected?
The proportionality principle is a major source of guidance in this task. An-
106. TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS
121 (3d ed. 1989).
107. BELMONT REPORT, supra note 7, at 7.
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other way to understand the function of the proportionality principle is to
see it working on second-order questions in research review. In prior review
of any research with human subjects, there is a first-order obligation to ask:
"Should this research be done at all?" To examine this question fully re-
quires attention to four of the five ethical principles that are shown in Table
2. Once good reasons for a "yes" appear, the risk-benefit issues can be more
fully treated in the context of proportionality. Turning to proportionality
issues too soon is a sign of avoidance of first-order questions.
Belmont also needs to re-examine its discussion of the tasks entailed in the
protection of human subjects. The Report discussed three tasks: informed
consent, risk-benefit assessment, and selection of subjects."08 These are
clearly indispensable tasks, but are there not two more? The Belmont Re-
port focused primarily on protection of human subjects. Who will be con-
cerned with the discussion of appropriate goals for research and protection
of the freedom of the pursuit of important biomedical knowledge by re-
searchers? The authors of the Belmont Report probably assumed that free-
dom of research was not a major issue in the research review process. The
EAB was designed to respond to long-range social and ethical issues embed-
ded in specific research projects; Institutional Review Boards (IRBs) were
seen as inappropriate to deal with these long-range issues. But who shall
address these tasks in view of the "moral vacuum" that exists at the national
level? When a controversial research protocol in fetal or embryo research
comes before an IRB, it also raises long-term social and ethical issues. In
fact, federal regulations permit the hiring of consultants or other experts to
consider special issues confronting an IRB.i°9 NIH's Office of Protection
from Research Risks (OPRR) has recognized that the absence of an EAB
creates a serious problem for controversial protocols that should be referred
to this national forum. In lieu of an EAB, the OPRR recommends aug-
menting the IRB with experts who can broaden the scope of discussion be-
yond the immediate riskbenefit analysis of the project." 0 As long as the
nation and its scientists are deprived of an EAB, the IRBs are the only pub-
licly accountable bodies for such discussions.
The prohibitions on the federal side of the wall should not be permitted to
freeze out research on the private side. To ensure the fullest scope of re-
search freedom on the private side-until the wall is removed-two tasks
can be added to IRBs: discussion of goals for research and protection of the
freedom to pursue important biomedical knowledge.
108. Id. at 10-20.
109. 45 C.F.R. § 46.107(f) (1991).
110. John C. Fletcher, How Abortion Politics Stifles Science, WASH. POST, Feb. 5, 1989, at
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In conclusion, the reader is referred to the four activities in Table 1.
These activities are ranked in the order of their clinical relevance to fetuses,
to live-born persons suffering from genetic or other diseases, and to future
development of human gene therapy. These are the research activities most
negatively affected by the wall of separation. When the wall is dismantled,
each activity will need to be ranked in a hierarchy of social priorities for
biomedical research. 1'
111. For a thorough discussion of the ethical, scientific, and political aspects of these issues,
see John C. Fletcher, Controversies in Research Ethics Affecting the Future of Human Gene
Therapy, 1 HUM. GENETIC THERAPY 307 (1990); John C. Fletcher, Fetal Tissue Transplanta-
tion Research and Federal Policy: A Growing Wall of Separation, 5 FETAL DIAG. THERAPY 211
(1990).
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